MOTS-c vs SS-31
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Mitochondrial ORF of the 12S rRNA type-c
A mitochondria-derived peptide that regulates metabolic homeostasis. Discovered in 2015, it is being studied for its effects on insulin sensitivity, exercise capacity, and aging.
Also: Elamipretide, Bendavia
A mitochondria-targeted peptide that improves cellular energy production. FDA approved for Barth syndrome (September 2025) as FORZINITY, the first approved mitochondria-targeted therapeutic.
Key Comparison Insights
- SS-31 is FDA approved, while MOTS-c remains in research stages.
- MOTS-c is categorized as Hormonal, while SS-31 is Anti-Aging.
- SS-31 has stronger research evidence (FDA Approved) compared to MOTS-c (Animal Studies).
Detailed Comparison
| Attribute | MOTS-c | SS-31 |
|---|---|---|
| Category | Hormonal | Anti-Aging |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | MOTS-c is encoded by mitochondrial DNA and acts as a mitokine, communicating mitochondrial status to the rest of the body. It activates AMPK, improves glucose uptake, enhances fatty acid oxidation, and has systemic metabolic regulatory effects. | SS-31 concentrates 1000-fold in mitochondria, binding to cardiolipin on the inner membrane. It optimizes electron transport chain function, reduces reactive oxygen species, and prevents cardiolipin peroxidation during cellular stress. |
| Common Dosing | 5-10 mg weekly 1-3x weekly | 40 mg subcutaneous daily Once daily |
| Administration | Subcutaneous injection | Subcutaneous injection or IV infusion |
| Typical Duration | Variable by protocol | Variable by condition |
| Best Time to Take | Morning or pre-workout | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Studies show MOTS-c improves insulin sensitivity and prevents diet-induced obesity in mice. Research demonstrates enhanced exercise capacity and protection against age-related metabolic decline. Human studies are limited but promising. | FDA approved for Barth syndrome in September 2025 under accelerated approval. Ongoing trials for dry age-related macular degeneration and primary mitochondrial myopathy. Studies show improved cardiac function, exercise capacity, and mitochondrial efficiency. |
Frequently Asked Questions: MOTS-c vs SS-31
What is the difference between MOTS-c and SS-31?
MOTS-c is a hormonal peptide that a mitochondria-derived peptide that regulates metabolic homeostasis. discovered in 2015, it is being studied for its effects on insulin sensitivity, exercise capacity, and aging. SS-31 is a anti-aging peptide that a mitochondria-targeted peptide that improves cellular energy production. fda approved for barth syndrome (september 2025) as forzinity, the first approved mitochondria-targeted therapeutic. The main differences lie in their mechanisms of action and clinical applications.
Which is better, MOTS-c or SS-31?
Neither is universally "better" - the choice depends on your specific goals. MOTS-c is typically used for hormonal purposes, while SS-31 is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can MOTS-c and SS-31 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using MOTS-c and SS-31 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.